News
Interim Report 2019
Continued strong growth towards profitability Integumen (LSE: SKIN), the vertically integrated skin product test services company, today announces its interim [...]
How AI is Revolutionising Healthcare and Skin Disease
We have entered a new era where an Artificially Intelligent (AI) Laboratory today is becoming more science, than science fiction. [...]
Cloning The Skin Microbiome On Labskin
Labskin breakthrough clones 16 human skin swabs into 54 living microbiome test subjects Labskin scientists cloned 16 swabs of skin [...]
Wound pHase CBD Infused Chronic Woundcare and Burns Products
Integumen today announces the expansion of its wound care division, LifeScienceHub Ltd (Wound pHase), as it extends its license technology [...]
Trading Update H1 2019
Strong H1 2019 Revenue Growth Continues Trading Update The positive results of major restructuring in H2 2018 has delivered accelerated [...]
Final Results 2018
Integumen (LSE: SKIN), today announces its final results for the year ended 31 December 2018. Highlights Total revenue £501k (including discontinued [...]
3 Labskin contracts with CBD
Integumen today announces that Labskin AI, the virtual laboratory platform, has entered into testing agreements with three new clients – [...]
Trading Update & Board Changes May 2019
Trading update – board changes Trading Update Integumen announces the resignation of Tony Richardson as Chairman and a director of [...]
Labskin Clones Human Skin Environment for Clinical Trials
Launch of Labskin human skin clone tests for Medical Device and Clinical Research trials Integumen today announces the roll-out of [...]
Appointment of Fionán Murray, as Group Sales Director
Fionán Murray has joined Integumen as Group Sales Director, and as a Director of the Company with a focus on [...]
Integumen Investor Event
Turner Pope Investor Evening Integumen is pleased to announce that Gerry Brandon, the Company’s CEO, will be presenting at an [...]
STOER For Men Rehydrates Skin in 24 Hours
Integumen today announces the completion of development and launch of a new dandruff test on its animal-free Labskin test platform. [...]
Acquisition of Rinocloud Transforms Labskin AI Platform
Proposed Placing and Subscription of £2.518m Acquisition, Placing & Subscription Integumen plc, (AIM: SKIN, is pleased to announce that the [...]
Labskin Deferred Loan Digital Automation Equipment Deal
Labskin secures digital automation and integration through £400,000 Cellulac – Integumen deferred loan agreement Integumen plc (AIM: SKIN), is pleased [...]
STOER For Men With CBD oil
Labskin CBD tests show greater than 99% reduction in bacterial growth on human skin Integumen plc (AIM: SKIN) is pleased [...]
Trading Update January 2019
Restructuring is Accelerating Growth into 2019 Trading Update The Company is pleased to announce the positive results of major restructuring [...]
TSpro Disposal Removes £1.19m Liabilities
Divestment of TSPro GmbH to remove c€1.34m (£1.19m) of short and long term liabilities from Integumen Today the Company announces [...]
Labskin On A Chip
Labskin-On-A-Chip to monitor real-time skin related diseases and Labskin-AI data analysis to predict the best course of treatment Integumen is [...]
Trading Update November 2018
Major Restructuring Causing Increased Growth The Company is pleased to announce the increased growth in product sales and contract test [...]
Artificially Intelligent Labskin
First laboratory-grown human-skin test service, to use artificial intelligence, to provide clinical validation for cosmetic, personal hygiene and skin care [...]
Trading Update August 2018
Chairman’s Statement Introduction Since Integumen’s admission to trading on AIM in April 2017, the integration of multiple isolated and diverse [...]
Interim Results 2018
Integumen (LSE: SKIN), the non-animal-testing, skin care and cosmetic businesses developing and commercialising technologies and products for consumer use today [...]